LONG $KRYS - IMA
One Platform. Multiple Diseases. No Competitors.
“So let me get to our dreams over the next 5 years. Our vision, you got to take a stand somewhere, it’s about 4 marketed rare disease products. We say a rare disease because one of the things the launch has done for us is to realize we’re really good. We’re really, really -- our capability competence is developing and commercializing rare diseases. I think we’re very convinced of that.”
- Krish S. Krishnan - Founder, Chairman, President & CEO of Krystal Biotech, Inc.
Investment Thesis
We initiated a BUY on Krystal Biotech (NYSE: KRYS) on April 16, 2026 at $267.41 per share. KRYS targets rare diseases, creating a strongly recurring revenue stream that has no competitors and is not easily replicable, if their product is successfully approved. Much of our view weighs on this “if”. KRYS currently has one commercialized product being VYJUVEK, and we believe that the market is giving minimal weighting to their pipeline and not properly valuing it as well as undercounting the potential growth of VYJUVEK.
Business Overview
To properly understand KRYS as a company, we must first understand how Biopharma platforms work. In short, they target indications, which is essentially the illness they are trying to solve. They go through three phases of studies, and assuming those three phases go well they will seek FDA approval. Their product is then commercially available, and the company starts being valued as a mix of their pipeline and the prospective sales and margins of their commercialized product.
Applying this concept to KRYS, they are a rare disease company, so they target indications of which there are no cures for. This means that if their product is fully developed, they will have a near monopoly on treatment for a very lucrative product. This can be demonstrated by VYJUVEK, where they treat DEB and receive ~$630,000 per patient annually.
Speaking on their pipeline, they are targeting seven different indications spread across Respiratory, Ophthalmology, Dermatology, and Oncology. We found what the market value of these products were, then assigned a percent probability chance of each of these drugs potentially succeeding. We saw that compared to industry averages, KRYS’s pipeline is significantly undervalued and could drive significant upside.
Why We Are Convicted on Their Pipeline - HSV-1 Vector
The question that everyone will have is why do we think that the drugs will succeed? And even if they do succeed, what are the chances they’ll be as lucrative as VYJUVEK? Both of the answers to this question point to their HSV-1 Vector. This vector is an engineered herpes simplex virus that serves as Krystal’s gene delivery vehicle. Unlike most gene therapy vectors, HSV-1 does not permanently integrate into the cell’s DNA, which means the immune system never builds a lasting defense against it. Patients can redose indefinitely, which is scientifically rare and commercially extraordinary. That’s the reason VYJUVEK is a weekly recurring treatment rather than a one-time cure.
In addition, it is scientifically revolutionary. When you are dosing a patient, there is two components – there is the actual data being dosed, aka. the “cure”, and then there is the delivery vehicle. HSV-1 is the delivery vehicle, but it carries significantly more data than any other delivery vehicle in the world. KRYS owns the patent and manufactures this vector in house. This leads to incredible margins that will be replicable across their entire pipeline, creating incredible upside given the success of one drug.
Consensus vs. Our View
Consensus is anchored on VYJUVEK, pricing in how much of the ~9,000 global population they can penetrate. Currently, KRYS treats ~660 of these patients, and the market is expecting 24% growth annually over the next three years. They further assign very little probability to two of their indications, and near zero to the rest.
We disagree with consensus on two elements. First, we expect that the patient growth of VYJUVEK will exceed expectations. For insurance firms to approve treating DEB, a patient must prove that they get injured from it (which is very easy to prove) and that they are missing the DNA strand that leads to having DEB. The latter component is an $1,500, out-of-pocket test that many older consumers are not willing to pay since they’ve lived with this condition all their life. KRYS in response has started a Decode DEB program, where they will find patients with DEB and pay for the test themselves – a $1,500 cost for $630,000 annually is a small cost to pay. That, alongside their international expansion efforts, should lead to revenue growth outpacing expectations.
Our second element is the pipeline valuation. As mentioned, many times earlier, the market is not properly pricing the potential of their pipeline. Rather than beat a dead horse, we’d love if you look at our appendix to see our valuation criteria.
Catalysts
Germany Pricing Resolution (Q3 2026): The single most concrete near-term catalyst. Every vial sold since August 2025 has been conservatively accrued. When final pricing is confirmed, Krystal will recognize the difference as a catch-up revenue event in one quarter. Management has flagged Japan’s successful negotiation as the benchmark. Positive surprise is likely.
KB801 and KB803 Eye Data (End of 2026): KB801 is targeting neurotrophic keratitis, a condition affecting 65,000 US patients where the only current treatment requires 8 clinic visits per day for 8 weeks. Peak revenue potential is $1.3–2.0B in the US. KB803 targets corneal abrasions in existing VYJUVEK patients. This has zero incremental patient acquisition cost, pure add-on revenue. A compassionate use patient went from near-blind to 20/25 vision in 8 months, published in the New England Journal of Medicine. Positive data from either program would force a complete re-rating of the business as a multi-product platform.
Italy Launch (2H 2026): As mentioned above, this will be clean revenue from day one. No accrual uncertainty. Every vial sold is booked at confirmed final price.
KB407 Cystic Fibrosis Phase 3 Enrollment (1H 2026): Phase 3 enrollment start signals the program is real, the FDA has blessed the trial design, and the path to approval is no longer theoretical. For the 3,500 modulator-ineligible CF patients with zero corrective options today, this is the only pipeline with any chance of working. Management called Phase 1 data a “breakthrough.”
Q1 2026 Earnings (May 2026): First-ever US vs. international revenue disclosure. Investors will see for the first time how fast the international business is actually scaling. If the number surprises to the upside relative to what the current consensus is implicitly modeling, it could be a significant positive catalyst by itself.
Valuation
Base Case - $407.17 (+52%): VYJUVEK scales to $560M in 2026 revenue and $790M by 2027, driven by continued US patient identification, international market ramp, and stable 95% gross margins. KB801 and KB803 deliver positive Phase 3 data by end of 2026, positioning both for commercialization beginning in 2027. Multiple expansion is gradual. The stock appreciates execution rather than a full platform re-rating. This is the conservative scenario where the eye programs work but the market remains anchored on VYJUVEK.
Bull Case - $523.29 (+96%): VYJUVEK outperforms as Decode DEB unlocks the adult undiagnosed population faster than expected and international revenue exceeds the $530M consensus estimate. KB801 and KB803 commercialize ahead of the 2027 timeline. The market begins to price Krystal as a scalable gene therapy platform rather than a single-asset biotech. Valuation re-rates materially on both earnings growth and multiple expansion, as investors start capitalizing pipeline success into the stock.
Bear Case - $128.89 (-52%): Pipeline faces delays or clinical failures. KB801 and KB803 produce negative or inconclusive data, eliminating their path to commercialization. VYJUVEK growth continues but without pipeline catalysts, the company fails to establish new revenue streams. The market continues to price KRYS as a single-asset biotech with a domestic ceiling of 3,000 patients. Valuation compresses toward or below the current enterprise value. 0% pipeline probability applied across all programs.
Risks and Mitigants
US Market Ceiling: The DEB patient pool is finite with roughly 3,000 US patients total. If Decode DEB fails to identify meaningful additional undiagnosed patients, domestic growth could plateau earlier than expected.
Mitigant: Only 1,200 of 3,000 US patients were formally identified at VYJUVEK’s launch. The program is finding patients. Three consecutive quarters of acceleration as of Q4 2025 confirm that growth is speeding up, not decelerating. Home administration further removes a structural barrier for rural and adult patients.
European Pricing Disappointment: Germany or France could negotiate lower-than-accrued prices, forcing Krystal to record a negative revenue adjustment that reverses prior accruals..
Mitigant: Management has stated explicitly that Japan’s successful negotiation is the benchmark for their conservative accrual approach. Japan finalized pricing before launch. Germany launched first and accrued conservatively. The skew is toward a positive surprise, not a negative one. Italy avoids this risk entirely since pricing is confirmed before launch.
Pipeline Clinical Delays: KB407 CF Phase 3 is the most capital-intensive and longest-duration program. A protocol delay or slower-than-expected enrollment would push the data readout and defer optionality value.
Mitigant: Phase 1 data was extraordinary. It showed 100% biopsy positivity and complete transduction across modulator-ineligible patients. The FDA is clearly engaged given the Phase 3 design has already been agreed. KB407 delay would be disappointing but does not impair the near-term VYJUVEK thesis or the 2026 eye catalysts.
Portfolio Manager: Ivan Parakkal
Analysts: Mukund Kasisomayajula, Jack Micaletti